LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Alvocidib | 10.0 | uM | LJP6 | 2 | A13 | 72 | hr | 1097 | 603 | 3769 | 0.1600 | -0.1850 |
| SK-BR-3 | Alvocidib | 10.0 | uM | LJP6 | 2 | A13 | 72 | hr | 1401 | 896 | 4223 | 0.2122 | -0.1792 |
| MCF 10A | Alvocidib | 3.33 | uM | LJP6 | 2 | A14 | 72 | hr | 962 | 224 | 10605 | 0.0211 | -0.0765 |
| MCF 10A | Alvocidib | 3.33 | uM | LJP6 | 1 | A14 | 72 | hr | 962 | 212 | 10605 | 0.0200 | -0.0778 |
| MCF 10A | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 962 | 1523 | 10605 | 0.1436 | 0.0582 |
| SK-BR-3 | Alvocidib | 3.33 | uM | LJP6 | 3 | A14 | 72 | hr | 1401 | 825 | 4223 | 0.1954 | -0.2043 |
| MCF 10A | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 962 | 1428 | 10605 | 0.1347 | 0.0483 |
| MCF7 | Alvocidib | 3.33 | uM | LJP6 | 3 | A14 | 72 | hr | 1209 | 652 | 4093 | 0.1593 | -0.1934 |
| MCF7 | Alvocidib | 3.33 | uM | LJP6 | 1 | A14 | 72 | hr | 1209 | 688 | 4093 | 0.1681 | -0.1809 |
| MCF 10A | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 962 | 1601 | 10605 | 0.1510 | 0.0662 |
| MCF 10A | Alvocidib | 3.33 | uM | LJP6 | 3 | A14 | 72 | hr | 962 | 176 | 10605 | 0.0166 | -0.0815 |
| BT-20 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1097 | 2016 | 3769 | 0.5348 | 0.3438 |
| MCF7 | Alvocidib | 3.33 | uM | LJP6 | 2 | A14 | 72 | hr | 1209 | 742 | 4093 | 0.1813 | -0.1622 |
| BT-20 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1097 | 1496 | 3769 | 0.3969 | 0.1492 |
| MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1235 | 1523 | 4513 | 0.3374 | 0.0876 |
| Hs 578T | Alvocidib | 3.33 | uM | LJP6 | 3 | A14 | 72 | hr | 658 | 380 | 3846 | 0.0988 | -0.0873 |
| MCF7 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1209 | 1383 | 4093 | 0.3379 | 0.0602 |
| BT-20 | Alvocidib | 3.33 | uM | LJP6 | 3 | A14 | 72 | hr | 1097 | 580 | 3769 | 0.1539 | -0.1936 |
| Hs 578T | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 658 | 686 | 3846 | 0.1784 | 0.0087 |
| Hs 578T | Alvocidib | 3.33 | uM | LJP6 | 1 | A14 | 72 | hr | 658 | 404 | 3846 | 0.1050 | -0.0797 |
| BT-20 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 1097 | 1632 | 3769 | 0.4329 | 0.2001 |
| MCF7 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1209 | 1439 | 4093 | 0.3516 | 0.0796 |
| MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1235 | 1507 | 4513 | 0.3339 | 0.0827 |
| Hs 578T | Alvocidib | 3.33 | uM | LJP6 | 2 | A14 | 72 | hr | 658 | 474 | 3846 | 0.1232 | -0.0578 |
| BT-20 | Alvocidib | 3.33 | uM | LJP6 | 1 | A14 | 72 | hr | 1097 | 680 | 3769 | 0.1804 | -0.1561 |